Pre-Conference Workshop Discussion
Monday, November 1, 2021
9.30 - 16.30 EST | 6.30 - 13.30 PST
Can we Reverse Fibrosis? Elucidating Novel Pathways to Promote Tissue Regeneration & Repair
9.30 - 11.30 EST | 6.30 - 8.30 PST
Research into regenerative medicine has reached a pivotal point as our physiological understanding of cells involved in fibrosis has drastically evolved.
New insights into fibroblast deactivation and senotherapeutics have opened novel avenues to therapeutically reverse fibrosis and may provide the key to truly progress tissue regeneration. Attend this workshop to evaluate cutting edge research into understanding and manipulating invasive fibroblasts and senescent cells to promote tissue remodeling.
- Targeting invasive fibroblasts in idiopathic pulmonary fibrosis: can we
- Identification of invasive fibroblasts in mouse and man
- Identification of targets to block invasion and impact on fibrosis
- How are genetic mutations driving the appearance of senescent cells in
Idiopathic Pulmonary Fibrosis?
- Illuminating mechanisms and functions of senescent cells in Idiopathic Pulmonary
- Fibrosis and advances in targeting these cells with novel senotherapeutics to reverse established fibrosis
Chair, Department of Medicine
Cedars Sinai Medical Center
Assistant Professor of Medicine
Harvard Medical School
Harnessing Single Cell RNA Sequencing to Unravel Fibrosis
in Systemic Sclerosis
12.00-14.00 | 9.00-11.00
Recent studies have demonstrated the value of single-cell sequencing in interrogating tissues at cell-level resolution, but there remain challenges in analyzing the wealth of information generated by single-cell experiments. Join this workshop to discover the latest techniques in single-cell sequencing and keep up with the evolving applications in fibrotic diseases.
- Aligning efforts in single-cell sequencing to define the cell types and mechanisms driving fibrotic remodeling in lungs and skin
- Advances in defining transcriptional regulation by analyzing transcriptomes and open chromatin
- Advances in characterizing fibroblast populations and identifying profibrotic macrophages through single-cell RNA sequencing
University of Pittsburgh
Arthur C. Curtis Professor of Skin Molecular Immunology
University of Michigan
What is an Approvable & Acceptable Endpoint for Clinical Trials in Fibrosis?
14.30 - 16.30 | 11.30 -13.30
There has been significant debate surrounding the optimal endpoint for demonstrating the efficacy of novel therapeutics to support antifibrotic drug development and the need to evaluate current regulations on clinical endpoints.
Do regulations do enough to allow for creative clinical trial design? To learn more, join this multi-stakeholder workshop and engage in the active discussion on identifying acceptable endpoints.
- Evaluating clinically meaningful endpoints and alternatives to invasive procedures to stimulate patient engagement in trials
- Considerations of EMA and FDA guidelines on acceptable endpoints
- Assessing strategies for engaging regulatory authorities in discussions on redefining approvable endpoints
Senior Regulatory Affairs Director
Executive Director/ Therapeutic Area Head Respiratory ILD Clinical Development & Medical Affairs